Pennsylvania

NeuExcell Therapeutics Raises Over $ 10 Million Series Before Round To Continue Growth For The Company | State

State College, Pennsylvania., August 30, 2021 / PRNewswire / -NeuExcell Therapeutics (www.neuexcell.com), A gene therapy company focused on neurodegenerative diseases has announced a Series Pre-A funding round of over $ 10 million. The round was led by Co-Win Ventures and was attended by other institutional investors Yuan Bio, Oriza Seed, Tsingyuan and Inno Angel.

“We are honored to join this very reputable group of investors,” he said. Peter Tombros, Chairman of the Board of Directors of NeuExcell Therapeutics. “Investor experience and support will enable us to leverage our unique neuroregenerative gene therapy platform across multiple neurodegenerative indications. This funding strength validates our strategy and biotechnology. Further examine our science in the industry. “

Professor Gong Chen, co-founder and chief scientific advisor of the company, said: “There is an urgent need for breakthrough therapies like us.”

“I think this is a great opportunity to invest in experienced leadership,” he said. Xin Huang, Managing Partner of Co-Win Ventures. “NeuExcell’s unique technology has the potential to act as a platform for treating many neurodegenerative diseases, providing hope for breakthrough new therapies for patients who do not have the right choices today. “

With the end of this successful pre-A round, we welcome him. Xin Huang Jonathan Sun attended the board meeting.

About NeuExcellTherapeutics

NeuExcell is a privately held early stage genetic engineering company headquartered in Pennsylvania, USA When Shanghai, China.. Its mission is to improve the lives of patients suffering from neurodegenerative diseases and damage to the central nervous system. Based on Professor Gong Chen’s scientific research, we have developed a potentially destructive nerve repair technique through the conversion of astrocytes to neurons. In vivo By introducing neural transcription factors through adeno-associated virus (AAV) -based gene therapy. NeuExcell’s pipeline covers major neurodegenerative diseases such as stroke, Huntington’s disease, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, spinal cord injury, and glioma. increase.

Founded in 2009, Co-Win Ventures is an early stage investor in healthcare and TMT with a focus on equality, transparency, sharing and innovation. Co-Win’s business network China When USA..Total AUM is about US $ 1 billion, Co-Win aims to be a reliable partner for great entrepreneurs to build breakthrough technologies and businesses. Co-Win Ventures has helped more than 140 portfolio companies, including leading leaders in their respective sub-sectors, including Cytek, Connect, Thrive (acquired by Nasdaq-listed company EXAS), Taimei Technology, Genecast, Sinovation and Augta. ..

Source NeuExcellTherapeutics

NeuExcell Therapeutics Raises Over $ 10 Million Series Before Round To Continue Growth For The Company | State

Source link NeuExcell Therapeutics Raises Over $ 10 Million Series Before Round To Continue Growth For The Company | State

Related Articles

Back to top button